期刊文献+

成都地区17家医院2006~2008年新药利用分析

Analysis of the Utilization of New Drugs in 17 Hospitals from Chengdu Area during 2006~2008
原文传递
导出
摘要 目的:了解成都地区17家医院2006~2008年新药的利用情况及趋势。方法:对成都地区17家医院2006~2008年新药的销售金额进行统计、分析。结果与结论:该地区医院新药的销售金额呈逐年上升趋势,年增长率分别为678.4%、280.6%;抗恶性肿瘤药、神经系统药和抗感染药的销售金额排在前3位;销售金额排序列前10位药品中,抗恶性肿瘤药、神经系统药、抗感染药在2006年有4种、2007年有7种、2008年有8种。在新药的应用过程中,除了应观察患者的临床疗效外,还应对其安全性给予特别关注。 OBJECTIVE:To evaluate the current situation of the utilization of new drugs in 17 hospitals from Chengdu area between 2006 and 2008.METHODS:Consumption sum of new drugs used in 17 hospitals of Chengdu area from 2006 to 2008 were analyzed statistically.RESULTSCONCLUSION:The consumption sum of new drugs in hospitals of Chengdu area were increased year by year with increasing rate of 678.4% in 2007 and 280.6% in 2008.Top 3 drugs in the list of consumption sum are anti-tumor drugs,nerve system drugs and anti-infective drugs.In the top 10 drugs in the list of consumption sum,anti-tumor drugs,nerve system drugs and anti-infective drugs posses 4 kinds of drugs in 2006,7 kinds in 2007 and 8 kinds in 2008.Great importance should be attached to safety of drug use as well as clinical efficacy.
出处 《中国药房》 CAS CSCD 北大核心 2010年第38期3567-3569,共3页 China Pharmacy
关键词 成都地区 新药 药物利用分析 Chengdu area New drugs Analysis of drug use
  • 相关文献

参考文献1

二级参考文献25

  • 1[1]Van Cutsem E, Cunningham D, Maroun J, et a1. Raltitrexed: current clinical status and future directions[J]. Ann Oncol, 2002,13(4) :513-522.
  • 2[2]Kempin S, Gutierrez J, Wilson E, et al. Raltitrexed (tomudex): an alternative choice in patients intolerant to 5 - fluorouracil [J]. Cancer Invest, 2002,20(7 - 8) :992 - 995.
  • 3[3]Lehman N L. Future potential of thymidylate synthase inhibitors in cancer therapy[J]. Expert Opin Investig Drugs, 2002, 11(12):1775- 1787.
  • 4[4]Rose M G, Farrell M P, Schmitz J C. Thymidylate synthase: a critical target for cancer chemotherapy[J]. Clin Colorectal Cancer, 2002,1(4):220 - 229.
  • 5[5]Dolmans D E, Fukumura D, Jain R K. Photodynamic therapy for cancer [J]. Nat Rev Cancer, 2003,3(5):380-387.
  • 6[6]Xu Y, Villalona-Calero M A. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity[J]. Ann Oncol, 2002,13(12): 1841 - 1851.
  • 7[7]Morris R, Munkarah A. Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancel[J]. Oncologist, 2002,7(Suppl 5):29 - 35.
  • 8[8]Kirstein M N, Turner P K, Stewart C F. Topoisomerase I interactive agents[J]. Cancer Chemother Biol Response Modif, 2002,20:99 - 123.
  • 9[9]Baker D E. Oxaliplatin: a new drug for the treatment of metastatic carcinoma of the colon or rectum[J]. Rev Gastroenterol Disord, 2003,3(1):31-38.
  • 10[10]Coutinho A K, Rocha L C M. Metastatic colorectal cancer: systemic treatment in the new millennium[ J ]. Cancer Control, 2003,10(3 ): 224- 238.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部